uniQure
Develops one-time AAV gene therapies for serious diseases with unmet needs.
Something off on this page? Send us feedback.
Profile
Develops one-time genomic medicines through an AAV platform and proprietary manufacturing. Its business pairs partnered HEMGENIX rights and supply with proprietary programs led by investigational Huntington’s therapy AMT-130.
Develops one-time genomic medicines for serious diseases through an AAV platform and proprietary manufacturing. The core business combines internal drug development with external commercialization, including a licensing and supply relationship with CSL Behring around HEMGENIX.
Advances proprietary programs led by AMT-130 for Huntington’s disease. That therapy remains investigational; the FDA communication identified its analysis as a potential basis for an accelerated-approval BLA, while further alignment on the confirmatory-study design was still required before the intended submission.
Operates from an Amsterdam origin with a U.S. public listing and a manufacturing facility in Lexington, Massachusetts. Glybera’s EU authorization expired after uniQure did not seek renewal because of lack of demand, distinguishing regulatory authorization from durable commercial demand.
Company facts
Key statistics
Year to date +108% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Barclays | Reiterate | Overweight | $65 | $60 | |
| Jul 30, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform | ||
| Jul 29, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform | ||
| Jun 29, 2026 | H.C. Wainwright | Target | $50 | $80 | ||
| Jun 25, 2026 | Mizuho Securities | Target | $33 | $68 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | −$0.82 | −$1.22 | −48.4% | $5.4M | $5.8M | +7.2% | +5.29% |
| May 5, 2026Q1 FY26 | −$0.88 | −$0.85 | +3.4% | $5.2M | $3.6M | −31.6% | +7.84% |
| Mar 2, 2026Q4 FY25 | −$0.93 | −$0.56 | +39.8% | $5.3M | $5.6M | +4.5% | −14.00% |
| Nov 10, 2025Q3 FY25 | −$0.85 | −$1.38 | −62.4% | $4.8M | $3.7M | −23.6% | +17.93% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $5.3M | $3.7M | $5.6M | $3.6M | $5.8M | |
| Gross profit | $1.4M | $4.6M | $3.3M | $2.2M | $3.3M | −$4.6M | |
| Operating income | −$39.3M | −$43.9M | −$51.0M | −$52.2M | −$44.3M | −$55.9M | |
| Net income | −$43.6M | −$37.7M | −$80.5M | −$37.1M | −$53.5M | −$81.1M | |
| Diluted EPS | −$0.82 | −$0.69 | −$1.38 | −$0.59 | −$0.85 | −$1.22 | |
| Gross margin | 87.4% | 87.5% | 89.2% | 38.8% | 93.9% | -78.0% | |
| Operating margin | -2,510.0% | -833.6% | -1,379.0% | -936.8% | -1,242.8% | -956.8% |
Fiscal years (4-quarter sums)FY21 $524.0M · FY22 $106.5M · FY23 $15.8M · FY24 $27.1M · FY25 $16.1M
Revenue by product · Q4 FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $810.3M · Total debt $62.8M · Total assets $985.1M · Shareholders' equity $324.1M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 69.37M · Float 62.23M · 89.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6.73M | 9.70% | 13F | Aug 14, 2026 |
| JPMorgan Chase & Co | 4.87M | 7.00% | 13G | Jul 16, 2026 |
| RTW Investments, LP | 3.94M | 5.70% | 13G | Aug 14, 2026 |
| Aberdeen Group plc | 3.68M | 5.91% | 13G | Jan 29, 2026 |
| G1 Execution Services, LLC | 3.54M | 5.70% | 13G | Feb 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Matthew C. Kapusta | director, officer: CEO, Managing Director | −21,082 | $45.16 |
| Jun 30, 2026 | Jack Kaye | director | −21,167 | $46.44 |
| Jun 30, 2026 | Walid Abi-Saab | officer: Chief Medical Officer | −30,000 | $46.42 |
| Jun 26, 2026 | Walid Abi-Saab | officer: Chief Medical Officer | −1,434 | $46.86 |
| Jun 25, 2026 | Matthew C. Kapusta | director, officer: CEO, Managing Director | −28,716 | $50.02 |
Peers
- PTC Therapeutics
Oral huntingtin-lowering program in global Phase 3
- Wave Life Sciences
Allele-selective mutant huntingtin-lowering program
- Alnylam Pharmaceuticals
Phase 1 RNAi program targeting HTT exon 1
- Neurocrine Biosciences
Approved once-daily treatment for Huntington's chorea
- Teva (ADR)
Approved VMAT2 inhibitor for Huntington's chorea
- Sarepta Therapeutics
First-in-human CNS-delivered siRNA HD program
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| uniQure | $49.46 | +1.55% | $3.38B | — | — | 181.0 | +11.0% |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| Alnylam Pharmaceuticals | $240.00 | +1.22% | $31.73B | 40.1 | 26.7 | 6.6 | +66.9% |
| Neurocrine Biosciences | $154.94 | +0.57% | $15.49B | 22.6 | 16.9 | 4.6 | +39.5% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Median | 40.1 | 26.3 | 5.2 | +19.3% |